Back to Journals » Therapeutics and Clinical Risk Management » Volume 12

Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant–palonosetron combination

Authors Janicki P

Received 19 December 2015

Accepted for publication 28 March 2016

Published 2 May 2016 Volume 2016:12 Pages 693—699


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Giandomenico Roviello

Peer reviewer comments 3

Editor who approved publication: Professor Garry Walsh

Piotr K Janicki

Department of Anesthesiology and Perioperative Medicine, Milton S Hershey Medical Center, Pennsylvania State University College of Medicine, Hershey, PA, USA

Purpose: The purpose of this review is to summarize and discuss the recently published data (both original studies and reviews) on the oral medication NEPA, consisting of netupitant (a neurokinin-1 receptor antagonist [NK1RA], 300 mg dose) and palonosetron (5-hydroxytryptamine [serotonin or 5HT] type 3 receptor antagonist [5HT3RA], 0.5 mg dose), in the prevention of the acute and delayed nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy.
Methods: This review was based on the very limited number of available published trials consisting of two Phase III studies and one Phase II dose-selecting trial.
Results: These studies demonstrated some therapeutic benefits of NEPA over related chemotherapy-induced nausea and vomiting (CINV) prophylaxis management, as well as its beneficial safety profile. In particular, compared with single-dose 0.5 mg palonosetron, the complete response rates for all phases of CINV for the first cycle of highly emetogenic chemotherapy (with cisplatin), as well as anthracycline–cyclophosphamide-based moderately emetogenic chemotherapy, were significantly higher for single-dose NEPA. The high efficacy of NEPA in terms of prevention of CINV continued throughout repeated cycles of highly and moderately emetogenic therapies.
Conclusion: It is currently recommended that patients who are administered highly emetogenic chemotherapy regimens should obtain a three-drug combination consisting of NK1RA, 5HT3RA, and dexamethasone. The recently available oral combination of NEPA plus dexa­methasone provides an additional pharmacological management option that could be considered in this scenario.

Keywords: chemotherapy-induced nausea and vomiting, palonosetron, netupitant, NEPA, safety, pharmacology, outcomes

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Other article by this author:

Readers of this article also read:

High-intensity focused ultrasound therapy in combination with gemcitabine for unresectable pancreatic carcinoma

Lv W, Yan T, Wang G, Zhao W, Zhang T, Zhou D

Therapeutics and Clinical Risk Management 2016, 12:687-691

Published Date: 2 May 2016

Diagnosis and screening of patients with hereditary angioedema in primary care

Henao MP, Kraschnewski JL, Kelbel T, Craig TJ

Therapeutics and Clinical Risk Management 2016, 12:701-711

Published Date: 2 May 2016

Lasers in tattoo and pigmentation control: role of the PicoSure® laser system

Torbeck R, Bankowski R, Henize S, Saedi N

Medical Devices: Evidence and Research 2016, 9:63-67

Published Date: 2 May 2016

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010